The inhibition of growth and metastasis of human pancreatic ductaladenocarcinoma by MART-10
DOI:
https://doi.org/10.61173/xkwdx917Keywords:
pancreatic ductal adenocarcinoma, MART-10, cadherin, orthotopic xenograftAbstract
Previous studies demonstrated that MART-10, an analog to the active form of vitamin D3, has anti-cancer properties in
anaplastic thyroid cancer (ATC). It can inhibit ATC’s metastasis by altering cadherin protein expression and preventing
the EMT process. This study aims to investigate the effect of MART-10 in a different system, pancreatic ductal
adenocarcinoma (PDAC), in both in vitro and in vivo conditions. Methods: The study will use two known PDAC cell
lines. The cells will be treated with increasing MART-10 for various durations. In vitro metastasis will be measured
by trans-well migration and Matrigel invasion assay, in vitro proliferation will be measured by CCK-8 assay, and the
interaction between MART-10 and PDAC will be investigated with Western blot. Mice will be injected with tumor
cells and treated with increasing MART-10; in vivo tumor growth and metastasis will be recorded weekly. The positive
control for the experiments is ADH-1 (Exherin), and the negative control is PBS in DMSO. Possible results: There
are three main possible results: (1) MART-10 inhibits the growth and metastasis of PDAC cells; (2) MART-10 acts as
a stimulant for PDAC growth and metastasis; (3) MART-10 has no significant effect on the growth and metastasis of
PDAC. Conclusion: The result of the study will provide important insight into the preclinical effectiveness of MART10 in PDAC; it also sets the basis for future clinical studies of the drug. Future studies should investigate the mechanism
underlying MART-10’s effectiveness in PDAC or search for drug combinations with MART-10 that synergize the
disease.
References
[1] Adamska, A., A. Domenichini, and M. Falasca, Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences, 2017. 18(7): p. 1338.
[2] Ushio, J., et al., Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics, 2021. 11(3): p. 562.
[3] Orth, M., et al., Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019. 14(1): p. 141.
[4] Sommariva, M. and N. Gagliano, E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor during EMT. Cells, 2020. 9(4): p. 1040.
[5] Takeichi, M., Cadherin Cell Adhesion Receptors as a Morphogenetic Regulator. Science, 1991. 251(5000): p. 1451- 1455. Dean&Francis
[6] Takeichi, M., Morphogenetic roles of classic cadherins. Current Opinion in Cell Biology, 1995. 7(5): p. 619-627.
[7] Mrozik, K.M., et al., N-cadherin in cancer metastasis, its emerging role in hematological malignancies and potential as a therapeutic target in cancer. BMC Cancer, 2018. 18(1): p. 939.
[8] Shintani, Y., et al., ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. International Journal of Cancer, 2008. 122(1): p. 71-77.
[9] Chiang, K.-C. and T. C Chen, The anti-cancer actions of vitamin D. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2013. 13(1): p. 126-139.
[10] Chiang, K.-C., et al., Hepatocellular carcinoma and vitamin D: A review. Journal of Gastroenterology and Hepatology, 2011. 26(11): p. 1597-1603.
[11] Deeb, K.K., D.L. Trump, and C.S. Johnson, Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews Cancer, 2007. 7(9): p. 684-700.
[12] Garland, C.F., et al., The Role of Vitamin D in Cancer Prevention. American Journal of Public Health, 2006. 96(2): p. 252-261.
[13] Mehta, R.G. and R.R. Mehta, Vitamin D and cancer. The Journal of Nutritional Biochemistry, 2002. 13(5): p. 252-264.
[14] Perlman, K.L., et al., 1α,25-dihydroxy-19-nor-vitamin D3, a novel vitamin D-related compound with potential therapeutic activity. Tetrahedron Letters, 1990. 31(13): p. 1823-1824.
[15] Chiang, K.-C., et al., MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. Cancer Letters, 2015. 369(1): p. 76-85.
[16] Chiang, K.-C., et al., MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro. The Journal of Steroid Biochemistry and Molecular Biology, 2014. 139: p. 54-60.
[17] Chiang, K.-C., et al., 19-Nor-2α-(3-hydroxypropyl)- 1α,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. Steroids, 2011. 76(13): p. 1513-1519.
[18] Yang, S.W., et al., MART-10, a newly synthesized vitamin D analog, represses metastatic potential of head and neck squamous carcinoma cells. Drug Des Devel Ther, 2016. 10: p. 1995-2002.
[19] Ono, K., et al., Efficient Synthesis of 2-Modified 1α,25- Dihydroxy-19-norvitamin D3 with Julia Olefination: High Potency in Induction of Differentiation on HL-60 Cells. The Journal of Organic Chemistry, 2003. 68(19): p. 7407-7415.
[20] Goumas, F.A., et al., Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. International Journal of Cancer, 2015. 137(5): p. 1035-1046.
[21] Nakajima, A., et al., Inhibition of peroxisome proliferatoractivated receptor γ activity suppresses pancreatic cancer cell motility. Cancer Science, 2008. 99(10): p. 1892-1900.
[22] Zimmerman, N.P., et al., Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. Molecular Carcinogenesis, 2015. 54(3): p. 203-215.
[23] Wen, Z., et al., High Expression of Interleukin-22 and Its Receptor Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2014. 21(1): p. 125-132.
[24] Fu, Y., et al., Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. Journal of Experimental & Clinical Cancer Research, 2018. 37(1): p. 130.
[25] Aiello, N.M., A.D. Rhim, and B.Z. Stanger, Orthotopic Injection of Pancreatic Cancer Cells. Cold Spring Harb Protoc, 2016. 2016(1): p. pdb.prot078360.
[26] Huynh, A.S., et al., Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One, 2011. 6(5): p. e20330.
[27] Pigula, M., et al., Size-dependent Tumor Response to Photodynamic Therapy and Irinotecan Monotherapies Revealed by Longitudinal Ultrasound Monitoring in an Orthotopic Pancreatic Cancer Model. Photochem Photobiol, 2019. 95(1): p. 378-386.
[28] Zhou, K.-X., et al., Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC. Journal of Immunology Research, 2021. 2021: p. 6694392.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
